Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
- PMID: 18676848
- PMCID: PMC2561279
- DOI: 10.1158/0008-5472.CAN-07-6849
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
Abstract
Metastatic breast cancer may emerge from latent tumor cells that remain dormant at disseminated sites for many years. Identifying mechanisms regulating the switch from dormancy to proliferative metastatic growth has been elusive due to the lack of experimental models of tumor cell dormancy. We characterized the in vitro growth characteristics of cells that exhibit either dormant (D2.0R, MCF-7, and K7M2AS1.46) or proliferative (D2A1, MDA-MB-231, and K7M2) metastatic behavior in vivo. Although these cells proliferate readily in two-dimensional culture, we show that when grown in three-dimensional matrix, distinct growth properties of the cells were revealed that correlate to their dormant or proliferative behavior at metastatic sites in vivo. In three-dimensional culture, cells with dormant behavior in vivo remained cell cycle arrested with elevated nuclear expression of p16 and p27. The transition from quiescence to proliferation of D2A1 cells was dependent on fibronectin production and signaling through integrin beta1, leading to cytoskeletal reorganization with filamentous actin (F-actin) stress fiber formation. We show that phosphorylation of myosin light chain (MLC) by MLC kinase (MLCK) through integrin beta1 is required for actin stress fiber formation and proliferative growth. Inhibition of integrin beta1 or MLCK prevents transition from a quiescent to proliferative state in vitro. Inhibition of MLCK significantly reduces metastatic outgrowth in vivo. These studies show that the switch from dormancy to metastatic growth may be regulated, in part, through epigenetic signaling from the microenvironment, leading to changes in the cytoskeletal architecture of dormant cells. Targeting this process may provide therapeutic strategies for inhibition of the dormant-to-proliferative metastatic switch.
Figures
Similar articles
-
Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention.Int J Mol Sci. 2022 Nov 11;23(22):13931. doi: 10.3390/ijms232213931. Int J Mol Sci. 2022. PMID: 36430404 Free PMC article. Review.
-
An in vitro system to study tumor dormancy and the switch to metastatic growth.J Vis Exp. 2011 Aug 11;(54):2914. doi: 10.3791/2914. J Vis Exp. 2011. PMID: 21860375 Free PMC article.
-
Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment.Cancer Res. 2010 Jul 15;70(14):5706-16. doi: 10.1158/0008-5472.CAN-09-2356. Epub 2010 Jun 22. Cancer Res. 2010. PMID: 20570886 Free PMC article.
-
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.J Clin Invest. 2014 Jan;124(1):156-68. doi: 10.1172/JCI70259. Epub 2013 Dec 9. J Clin Invest. 2014. PMID: 24316974 Free PMC article.
-
Regulation of dormancy during tumor dissemination: the role of the ECM.Cancer Metastasis Rev. 2023 Mar;42(1):99-112. doi: 10.1007/s10555-023-10094-2. Epub 2023 Feb 21. Cancer Metastasis Rev. 2023. PMID: 36802311 Free PMC article. Review.
Cited by
-
Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention.Int J Mol Sci. 2022 Nov 11;23(22):13931. doi: 10.3390/ijms232213931. Int J Mol Sci. 2022. PMID: 36430404 Free PMC article. Review.
-
Plasma Fibronectin Promotes Tumor Cell Survival and Invasion through Regulation of Tie2.J Cancer. 2013 Jun 21;4(5):383-90. doi: 10.7150/jca.6545. Print 2013. J Cancer. 2013. PMID: 23833683 Free PMC article.
-
TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.Oncogene. 2013 Apr 18;32(16):2005-15. doi: 10.1038/onc.2012.230. Epub 2012 Jun 18. Oncogene. 2013. PMID: 22710711 Free PMC article.
-
The emerging molecular machinery and therapeutic targets of metastasis.Trends Pharmacol Sci. 2015 Jun;36(6):349-59. doi: 10.1016/j.tips.2015.04.001. Epub 2015 May 1. Trends Pharmacol Sci. 2015. PMID: 25939811 Free PMC article. Review.
-
Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.Cancer Res. 2015 Jun 1;75(11):2316-2325. doi: 10.1158/0008-5472.CAN-14-3485. Epub 2015 Apr 9. Cancer Res. 2015. PMID: 25858145 Free PMC article.
References
-
- Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419–24. - PubMed
-
- Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802. - PubMed
-
- Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol. 2001;11:297–306. - PubMed
-
- Goldberg SF, Harms JF, Quon K, Welch DR. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis. 1999;17:601–7. - PubMed
-
- Naumov GN, MacDonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002;62:2162–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous